Susceptibility of Mice to Trypanosoma evansi Treated with Human Plasma Containing Different Concentrations of Apolipoprotein L-1 by Da Silva, Aleksandro S. et al.
427
© 2011, Korean Society for Parasitology
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Trypanosoma evansi is a hemoprotozoan flagellate causing 
trypanosomosis in a variety of mammalian hosts [1]. This par-
asite has a wide geographic distribution and causes severe dis-
eases in animals of significant tropical areas, especially Africa 
and Latin America [2]. T. evansi is spread mainly by species of 
bloodsucking flies (Tabanus sp., Chrysops sp., and Hematopota 
sp.) and hematophagous bats [3].
Humans were considered refractory to infection by T. evansi 
[4], but a case of human infection was reported in an Indian 
farmer in 2005 [5]. After this case, researchers found in an In-
dian village, about 22% of the population positive for the par-
asite through blood smears and serology techniques [6]. It is 
known that humans have innate immunity against T. brucei. 
Researchers attributed this condition due to the presence of 
apolipoprotein L-1 (APOL1) in human blood, and this pro-
tein would have a trypanocidal factor, since it has the ability to 
lyse T. brucei [7]. In the case reported by researchers [5], later 
was found APOL1 deficiency in the blood, which could have 
contributed to the development of the disease [8]. Our resear-
ch group recently found that mice infected with T. evansi, when 
exposed to human plasma and blood, had their longevity ex-
tended, and some animals shed the parasite [9,10]. In view of 
these findings, this study aimed to assess the susceptibility of 
mice to T. evansi treated with human plasmas with different 
concentrations of APOL1.
A strain of T. evansi from a naturally infected dog [11] was 
used in this experiment. One Wistar rat was infected intraperi-
toneally with 0.2 ml of blood (10
6 parasites/animal) cryopre-
served in liquid nitrogen. This procedure was performed to 
obtain a larger number of parasites in the blood for further 
testing in vivo.
The plasma used in this study was obtained from 3 clinically 
healthy men, aging 23 (plasma 1), 25 (plasma 2), and 27 (plas-
ma 3) years old; all of them with A+ blood type. Blood was 
ISSN (Print)  0023-4001
ISSN (Online)  1738-0006
Korean J Parasitol Vol. 49, No. 4: 427-430, December 2011   
http://dx.doi.org/10.3347/kjp.2011.49.4.427 ▣BRIEF COMMUNICATION
Susceptibility of Mice to Trypanosoma evansi Treated with 
Human Plasma Containing Different Concentrations of 
Apolipoprotein L-1
Aleksandro S. Da Silva
1,*, Vinicius R. Fanfa
1, Mateus A. Otto
1, Lucas T. Gressler
1, Kaio C.S. Tavares
2, 
Cícera R. Lazzarotto
2, Alexandre A. Tonin
1, Luiz C. Miletti
2, Marta M. M. F. Duarte
3 and Silvia G. Monteiro
2
1Department of Microbiology and Parasitology, Universidade Federal de Santa Maria, Brazil; 
2Laboratory of Hemoparasites and Vectors 
Biochemistry, Universidade do Estado de Santa Catarina, Lages, Brazil; 
3Lutheran University of Brazil - ULBRA, Santa Maria, RS, Brazil
Abstract: The aim of this study was to test the susceptibility of mice to Trypanosoma evansi treated with human plasma 
containing different concentrations of apolipoprotein L-1 (APOL1). For this experiment, a strain of T. evansi and human 
plasma (plasmas 1, 2, and 3) from 3 adult males clinically healthy were used. In vivo test used 50 mice divided in 5 groups 
(A to E) with 10 animals in each group. Animals of groups B to E were infected, and then treated with 0.2 ml of human 
plasma in the following outline: negative control (A), positive control (B), treatment with plasma 1 (C), treatment with plas-
ma 2 (D), and treatment with plasma 3 (E). Mice treated with human plasma showed an increase in longevity of 40.9±0.3 
(C), 20±9.0 (D) and 35.6±9.3 (E) days compared to the control group (B) which was 4.3±0.5 days. The number of surviv-
ing mice and free of the parasite (blood smear and PCR negative) at the end of the experiment was 90%, 0%, and 60% 
for groups C, D, and E, respectively. The quantification of APOL1 was performed due to the large difference in the treat-
ments that differed in the source plasma. In plasmas 1, 2, and 3 was detected the concentration of 194, 99, and 115 mg/dl 
of APOL1, respectively.  However, we believe that this difference in the treatment efficiency is related to the level of APOL1 
in plasmas.
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collected into tubes containing anticoagulant (EDTA 10%), and 
centrifuged to separate plasma, which was stored in tubes in 
liquid nitrogen. The state of health of humans was confirmed 
by complete blood count, and liver and renal biochemical anal-
ysis. Were also evaluated by a doctor, and clinical examination 
was normal (clinically healthy humans, and hematological and 
biochemical tests unchanged). 
For the in vivo test 50 mice divided into 5 groups with 10 
animals in each group were used: negative control (A), posi-
tive control (B), and human plasma: T2 (C), T3 (D), and T4 
(E). The volume of 0.1 ml of blood from the Wistar rat con-
taining 2.4×10
6 trypanosomes was administered to mice of 
groups B to E, intraperitoneally. Then, 24 hr post-inoculation, 
treatments were carried out with different plasmas. The dose 
used in the treatment was 0.2 ml of plasma for groups C, D, 
and E, intraperitoneally. These animals were monitored daily 
by blood smears stained with Quick Panoptic and analyzed at 
100×magnification [12], during 41 days of the experiment. 
This study evaluated the mean and SD of the prepatent period, 
longevity, mortality, and success of treatments in mice experi-
mentally infected with T. evansi after treatment with human 
plasma. Data were subjected to analysis of variance (ANOVA) 
followed by the Tukey test.
The technique of immunoassay, i.e., quantitative sandwich-
ELISA, was used. Monoclonal antibodies specific for APOL1 in 
a plate ELISA (anti-APOL1 antibody produced in goat) (Sigma-
Aldrich, St. Louis, USA). The samples (100 µl) were pipetted, 
with the standards and the conjugates bound by peroxidases 
enzymes forming an antibody-antigen-antibody conjugate. Sub-
sequently, the plate was washed in microplate washer (Aware-
ness®) to remove any unbound substance, and then was added 
to a solution containing substrate (tetramethylbenzidine + hy-
drogen peroxide), observing the color development propor-
tional to the amount of APOL1 linked. The reaction was stabi-
lized by the addition of sulfuric acid (2 N) and the color inten-
sity measured by an ELISA reader (Biotek®) (Biotek, Nevada, 
USA). The results were expressed as APOL1 mg/dl, and the cal-
culations made from standard curves as a guidance kit, using 
SPSS version 10.0.
Genomic DNA was extracted from the brains using the phe-
nol-chloroform method [13] and subjected to electrophoresis 
on agarose gel at 1% for determining the quality and quantifi-
cation of samples. PCRs were performed using primers specific 
for T. evansi [14]; Te664a (5´ GTC AAA CCC CTC TTG GAG G 
3´) and Te664b (5´ CAT ATC CTA AGA GTT GT 3´) at a concen-
tration of 1 µm each, 1.5 U of Platinum Taq DNA Polymerase 
(Invitrogen, São Paulo, Brazil) with 1×reaction buffer, 1.5 mM 
MgCl2, 250 mm in each dNTP, and 1 µl of DNA. The reactions 
were subjected to an initial denaturation at 95˚C for 3 min, fol-
lowed by 35 cycles consisting of 3 steps; 95˚C for 1 min, 56˚C 
for 1 min, and 72˚C for 1 min. Finally, we perform  ed a final 
extension at 72˚C for 10 min. The amplified samples were ana-
lyzed by electrophoresis on 1% agarose gel at 80V for 1 hr, stain-
ed with ethidium bromide and photographed under UV light. 
As a positive control, we used DNA from T. evansi purified by 
chromatography on DEAE-cellulose, and sterile ultrapure wa-
ter was used as a negative control instead of DNA. 
In mice treated with human plasma, an increase in the ani-
mal longevity was observed when compared to the positive 
control group (Table 1). During the 41 days of experiment, the 
mortality was observed in all mice of groups B and D. Group 
C and E had 1 and 4 animals dead, respectively. In the nega-
tive control (group A), no mice died.
The quantification of APOL1 was performed due to the large 
difference in the treatments that differed in the source plasma 
(Table 1). In plasmas 1, 2, and 3 was detected the concentra-
tion of 194, 99, and 115 mg/dl of APOL1, respectively. For men, 
the references value of APOL1 oscillated within 107-214 mg/dl.
Nine animals of group C and 6 mice from group E subjected 
to PCR showed negative results for the parasite (Fig. 1). There-
fore, there were observed efficiencies of 90% (group C), 0% 
(group D), and 60% (group E) of plasma treatment against T. 
evansi (Table 1). At the end of the experiment, the rats were 
alive, and PCR and blood smear were negative.
Our research group has been investigating in recent years al-
ternative treatments for therapy of infections caused by T. evansi. 
The main reason for these investigations is the fact that the or-
Table 1. Media and standard deviation of the pre-patent period, 
longevity, mortality and success of therapy using treatment with 
human plasma in mice experimentally infected with T. evansi
Groups 
(n=10)
Treatment
Pre-patent 
period
Longevity Mortality
Success of 
therapy (%)
a
A Negative control - 41.0
a (±0.0) 0/10 -
B Positive control 1.9
a (±0.3) 4.3
c (±0.5) 10/10 -
C T2 1.9
a (±0.3) 40.9
a (±0.3) 1/10 90.0
D T3 1.6
a (±0.4) 20.0
b (±9.0) 10/10 0.0
E T4 1.4
a (±0.5) 35.6
a (±9.3) 4/10 60.0
Means followed by same letters in the same column do not differ signifi-
cantly in the Tukey’s test.
aIt was considered a therapeutic success when the animals survived for 
41 days with negative blood smears and PCR was negative for the para-
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dinary chemotherapy with diminazene aceturate, dipropionate 
imidocarb, and suramim, commonly used in the treatment of 
trypanosomosis, has been shown ineffective in many cases 
[15-17]. According to researchers, these drugs have limited ef-
fectiveness, due not to exceed the hematoencephalic barrier, a 
refuge area to the flagellate during the residual period of the 
drugs; or excess the barrier, but in insufficient dose to combat 
the parasite [18,19]. Therefore, research on herbal medicine, 
immunotherapy, and new chemical compounds are needed in 
attempting to combat T. evansi, which is expanding in Brazil 
[17].
In vitro tests with human plasma showed trypanocidal ef-
fects on T. evansi in different trials [20]. This effect of human 
plasma on the parasites is attributed to the presence of APOL1, 
which according to researches, have trypanocidal action [7]. 
Thus, APOL1 would be absorbed by the parasite by endocyto-
sis, which triggers the formation of selective anions in the pores 
of the lysosomal membrane, which lead to induction of an 
uncontrolled proliferation and osmotic swelling of this com-
partment with subsequent cell death by lysis of trypanosome 
[7,8,21]. Probably this was the mechanism by which the human 
plasma had an action of anti-trypanosome against T. evansi, as 
well as trypanocidal activity of human plasma on T. brucei [8].
Tests in mice infected with T. evansi showed differences be-
tween groups (plasma) to the longevity and therapeutic effica-
cy. Similar to other studies in rats and mice [9,10], the para-
sites disappear from circulation within 24 hr post-administra-
tion of treatment with plasma, and they had extended their 
longevity. However, when treatments were compared, animals 
of groups C (90%) and E (60%) left free of the parasite and 
longevity increased. By the other hand, all mice of group D 
had a recurrence of parasitemia and died of trypanosomosis. 
Since the volume of plasma administered was the same among 
groups, it is possible that the difference was due to the differ-
ent amount of APOL1 in plasma of each man. This hypothesis 
has greater acceptance when the protein was quantified in sam-
ples of plasma and showed a great difference in concentration 
of APOL1. The highest concentrations of the protein were de-
tected in plasma 1 (194 mg/dl) and 3 (115 mg/dl), exactly the 
samples which were more effective and curative for infected 
mice with T. evansi (group C and E). The plasma 2, showed no 
curative effectiveness and had the lowest concentration of AP-
OL1. This study emphasizes the fact that humans are refracto-
ry to T. evansi, due to the presence of blood APOL1 [8].
Besides APOL1 which is one of the 2 primate specific pro-
teins, however, TLF-1 also contains haptoglobin (Hp)-related 
protein (Hpr), as well as apolipoprotein A-1 (APOA1) which 
are both directly and indirectly related to the toxicity to trypa-
nosomes. Another related protein complex, TLF-2, although 
poorly characterized, is also likely to contribute to trypano-
some killing [22-24].
Based on these results, we conclude that T. evansi is suscepti-
ble to treatment with human plasma in vivo. Treatment with 
human plasma prolongs the survival of mice infected with T. 
evansi, but the curative effectiveness differs according to the plas-
mas used. Probably this difference among groups is related to 
levels of APOL1 in plasma.
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Fig. 1. Diagnosis of Trypanosoma evansi in blood samples of a mice experimentally infected and treated with human plasma, using 
the PCR. (MP) 100 pb ladder (Ludwig Biotec
®); (1-9) blood samples of group C post-treatment; (10-15) blood samples of group E 
post-treatment. (CN) negative control and (CP) positive control for T. evansi-315 pb.
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